Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
10 participants
INTERVENTIONAL
2021-05-19
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
NCT02089256
Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
NCT04854083
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
NCT01686945
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
NCT07171723
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
5 study subjects receive once 7 mg of oral semaglutide and once placebo. 5 study subjects receive once 14 mg of oral semaglutide and once placebo. The study group and order of administration of study medication are decided on randomization. The placebo and oral semaglutide are administered at least 4 weeks apart.
Blood samples are taken before and during 4 hours after the study medication administration (at 60, 90, 120, 150, 180, and 240 minutes after study medication administration).
The primary endpoint is the peak value of growth hormone measured during the 4 hours after study medication administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral semaglutide 7 mg
The semaglutide 7 mg tablet taken orally with upto120 ml of water.
Semaglutide 7 MG Oral Tablet
Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
Placebo
The placebo tablet taken orally with 120 ml of water.
Placebo
Placebo tablet is taken after an overnight fast with up to120 ml of water.
Oral semaglutide 14 mg
The semaglutide 14 mg tablet taken with upto 120 ml of water.
Semaglutide 14 MG Oral Tablet
Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semaglutide 7 MG Oral Tablet
Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
Placebo
Placebo tablet is taken after an overnight fast with up to120 ml of water.
Semaglutide 14 MG Oral Tablet
Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The body weight \>65 kg
Exclusion Criteria
* the daily use of medications
* pregnancy
* lactation.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tartu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vallo Volke
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vallo Volke, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Tartu
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tartu University Hospital
Tartu, , Estonia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sema21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.